The future of the global parkinson disease market looks promising with opportunities in the carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics markets. The global parkinson disease market is expected to reach an estimated $8.8 billion by 2030 with a CAGR of 6.1% from 2024 to 2030. The major drivers for this market are rising aging population, advances in diagnostic technologies, and increasing healthcare expenditure in emerging economies.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the parkinson disease market
by drug class (carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT
inhibitors, anticholinergics, and others), distribution channel (hospital
pharmacy, retail pharmacy, and online pharmacy), and region (North America,
Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market, hospital
pharmacy, retail pharmacy, and online pharmacy are the major segments of
parkinson disease market by distribution channel. Lucintel forecasts that
retail pharmacy will remain the largest segment over the forecast period due to
ease of availbility.Within this market, carbidopa-levodopa drug class will
remain the largest segment due to elevated rate of prescription for these
medications.
North America will
remain the largest region over the forecast period due to large number of
important participants, high disposable income, high costs for healthcare, and
an established healthcare system in this area.
Cerevel Therapeutics,
Novartis, Teva Pharmaceutical Industries, Merck & Co., Glaxosmithkline,
Abbvie, and H. Lundbeck are the major suppliers in the parkinson disease
market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Explore Our Latest Publications
Cutaneous Bcell
Lymphoma Treatment Market
Glioblastoma
Multiforme Market
No comments:
Post a Comment